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A B S T R A C T
High grade gliomas (HGGs) are aggressive primary brain tumours with local invasive growth and poor clinical
prognosis. Clinical outcome is compounded by resistance to standard and novel therapeutics. We have evaluated
reformulated aspirin (IP1867B) alone and in combination with conventional and novel anti-aHGG agents. We
show that recent biopsy-derived aHGG models were highly resistant to conventional therapeutics although show
sensitivity to IP1867B, a reformulated “liquid” aspirin. IP1867B treatment mediated a potent suppression of the
IL6/STAT3 and NF-κB pathways and observed a significant reduction in EGFR transcription and protein ex-
pression. We observed the loss of the insulin-like growth factor 1 and insulin-like growth factor 1 receptor
expression at both the transcript and protein level post IP1867B treatment. This increased sensitivity to EGFR
inhibitors. In vivo, IP1867B was very well tolerated, had little-to-no gastric lesions versus aspirin and, directed a
significant reduction of tumour burden with suppression of EGFR, IGF1 and IGFR1. With EGFR inhibitors, we
noted a potent synergistic response in aHGG cells. These data provide a rationale for further investigation of
IP1867B with a number of anti-EGFR agents currently being evaluated in the clinic.
1. Introduction
In 2017, 80,000 patients in the US and 11,400 in the UK were di-
agnosed with a primary brain tumour [1,2]. Paediatric high grade
glioma frequency in the US are 5.7 cases per 100,000. Adult HGG
treatment comprises surgical resection and combined radio- and
chemo-therapy [3,4]. The standard chemotherapeutic is temozolomide
(Temodal< SUP>TM</SUP>) (TMZ), an oral DNA alkylating
agent [5–7]. TMZ and radiotherapy (the “Stupp protocol”) demon-
strated significant patient survival benefit versus radiotherapy alone,
showing a median increase in survival of 2.5 months [3,4,8]. Cohort
analysis revealed a discernible clinical response only in adult high
grade glioma (aHGG) patients exhibiting promoter methylation of O6-
methylguanine DNA methyltransferase (MGMT) [9]. Irrespective of
MGMT promoter methylation, almost all aHGG patients exhibited
eventual disease progression. An area that has attracted attention is the
repurposing of Food and Drug Administration (FDA) approved agents
for difficult-to-treat cancers, in particular high grade gliomas [10–12].
Aspirin (acetylsalicylic acid, ASA) is a nonsteroidal anti-in-
flammatory drug which inhibits the cyclooxygenase (COX) enzymes
COX-1 and COX-2 [13] and has been implicated in anti-cancer re-
sponses [14]. Aspirin use post-diagnosis improved patient outcome,
suggesting a role with conventional therapies [15]. The long-term use
of aspirin reduced the cancer risk in paediatric patients with constitu-
tional mismatch repair deficiency who are predisposed to cancer de-
velopment [16]. There are over 20 registered clinical trials of aspirin for
cancer therapy [17]. Aspirin solubility is low (1 g in: 300mL water at
25< SUP>O</SUP>C) and there are serious concerns regarding
gastrointestinal (GI) injury in patients prescribed aspirin long-term.
Even low dose aspirin can induce duodenal mucosal injury including
ulcers or haemorrhages.
Approximately 50% of aHGG display EGFR amplification. Further, a
number of aHGGs express a truncated EGFR (EGFRvIII) protein which is
generated following the removal of exons 2–7 [18,19] that displays
constitutive, ligand-independent tyrosine kinase activity [20]. Insulin
Like Growth Factor 1 Receptor (IGF1R) is rarely mutated or amplified
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in aHGG [21], where, activation of this network is considered ligand-
dependant via endocrine mechanisms. IGF1R targeting has a significant
impact on AKT signalling in aHGG [22], and is implicated in EGFR
inhibitor resistance [23].
We report that IP1867B (ASA/triacetin/saccharin) directed a potent
anti-aHGG response in vitro and in vivo. This was via suppression of the
IL6/STAT3, NF-κB, IGF1/IGFR1 signalling networks. IP1867B exposure
induced the down regulation of EGFR, at both protein and transcript
level. IP1867B was well tolerated in non-neoplastic astrocytes and
showed no associated in vivo GI toxicity. IP1867B synergised with EGFR
inhibitors and in combination with IGF1R inhibitors had no additive
effect.
2. Materials and methods
2.1. Tumour specimens and primary tumour cultures
Adult HGG biopsy samples were obtained from patients undergoing
biopsy surgery at Kings College Hospital NHS Foundation Trust (LREC
review board (11/SC/0048) London, UK). Tumours were classified
based on WHO criteria [1] after examination by neuro-pathologists.
Tumour mass was mechanically dissociated into explant clumps, in-
cubated at 37 °C to allow neoplastic cells to colonize the flask/cell
culture plates. Medium was changed every 2 days. When neoplastic
cells reached confluence, cells were passaged and expanded. Once
passage 1 cells were obtained, Short Tandem Repeat (STR) analysis was
conducted to enable subsequent cell line authentication (Agilent
Bioscience).
2.2. Chemotherapeutics and cell culture
IP1867B (Innovate Pharmaceuticals), TMZ (T2577), vincristine
(V0400000) and aspirin (Sigma-Aldrich). Gemcitabine (S1714),
Gefitinib or AZD3759 (SelleckChem). Adult glioma cell line U87MG
was obtained from the ATCC and maintained in DMEM supplemented
with 10% heat inactivated FCS (Sigma-Aldrich). Novel aHGG biopsy-
lines UP-029, SEBTA-003, SEBTA-023 and SEBTA-025 were cultured in
DMEM medium. CC2565 non-neoplastic astrocytes (Lonza) were
maintained in astrocyte growth medium supplemented with
SingleQuots™ (CC-3187 Lonza) including (CC-4123): rhEGF, insulin,
ascorbic acid, L-glutamine. Cells were cultured under normoxic (21%)
or hypoxic (1%) O2 conditions.
2.3. MTS cell viability assay
5×103 cells were seeded in triplicate in a 96 well plate. 24 h post
seeding, cell lines were treated with each agent. CellTiter 96® AQueous
One Solution MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethox-
yphenyl)-2-(4-sulfophenyl)-2H-tetrazolium)) Reagent (G3580
Promega) was added and absorbance at 490 nm recorded.
2.4. Western blot analysis
Cells were harvested and lysed using RIPA buffer (89900, Thermo-
Fisher) and 1x protease inhibitor cocktail (78442 Thermo-Fisher). 50 μg
total protein was loaded per sample and separated by SDS-PAGE.
Proteins were transferred onto PDVF membrane (BioRad). Membranes
were blocked for 1 h at room temperature (RT) in Odyssey blocking
buffer (972–46100 LICOR). Primary antibodies (Supplemental Table 1)
were added overnight at 4 °C. Secondary antibody were added (LICOR)
at 1:10000 dilution for 1 h at RT and membranes imaged on an Odyssey
CLX (Licor). All uncropped immunoblots are shown in Supplemental
Figs. 1–5.
2.5. Quantitative real time PCR
Total RNA was extracted (RNAeasy, 74104 Qiagen) and measured
using RNA6000 chip (Agilent Bioscience, UK). 0.5 μg total RNA was
used per cDNA synthesis reaction (iScript cDNA synthesis kit, 1708890
BioRad). Real Time PCR was performed using a LightCycler 96 (Roche)
(iTaq SYBR Green, 1725120 BioRad). Primer sequences shown in
Supplemental Table 1. Data analysis was carried out using the 2-ΔΔCT
method [24].
2.6. RT2 pathway transcriptomics and analysis
Total RNA was extracted per condition (NT, 6hr IP1867B) using the
RNeasy Plus Mini Kit (Qiagen) including genomic DNA removal. The
quantified by RNA 6000 Nano Kit (Agilent, UK). 0.5 μg of RNA was used
for RT2 cDNA (Qiagen, UK). cDNA was added on the cell death Pathway
Finder (PAHS-212Z), NF-κB signalling array (Qiagen, PAHS-025Z) and
IL6/STAT3 signalling pathway (PAHS-160Z). Plates were run using a
Light Cycler 96 (Roche, UK). The CT values were obtained and fold
changes determined by 2-ΔΔCT [24].
2.7. In vivo anti-tumour efficacy
250,000 U87-luciferase cells were inoculated (intra-cranially) into
NOD/SCID mice (aged 10–12 weeks). Animals were grouped based on
luciferase imaging. Treatment was initiated every three days via IP
injection, PBS, TMZ 50mg/kg/day or IP1867B 30mg/kg/day. In vivo
bioluminescent imaging was performed once per week and all animals
were weighed with behaviour and neurological signs (including altered
gait, tremors, seizures and/or lethargy) monitored daily. This animal
study was conducted with Institutional and Home Office ethical ap-
proval.
2.8. In vivo gastric studies
Female C57BL/6 mice (aged 10–12 weeks, n= 2–3 mice/group)
were fasted for 16 h and oral gavaged daily for 5 consecutive days with
1% methylcellulose (10mL/kg), IP1867B (30mg/kg) or aspirin
(30mg/kg). All animal studies were conducted with Home Office
ethical approval. Stomachs were extracted and opened along their
greater curvature and pinned to a bed of paraffin and formaldehyde
fixed. Stomachs were cut into strips containing antrum and corpus and
processed for standard H&E staining. Non-serial sectioned gastric mu-
cosae were assessed for lesion number (521 ± 112 mm/stomach). All
animal studies were conducted with Institutional and Home Office
ethical approval.
2.9. Data analysis and statistics
Studies were analysed using GraphPad Prism and are represented as
mean ± St.Dev. Statistical significance calculated using Student's t-
test, (*P≤ 0.05), two-tailed ANOVA analysis, or the log-rank test for
Kaplan Meier survival analyses.
3. Results
3.1. IP1867B demonstrates a potent in vitro anti-aHGG effect under both
normoxic and hypoxic conditions
We investigated how novel biopsy-derived aHGG responded to each
excipient, IP1867B and temozolomide (TMZ) (Fig. 1). 96 h post drug
treatment MTS viability assays were conducted and EC50 values de-
termined (Fig. 1A–D). Saccharin did not affect cell viability at even the
highest tested concentration of 36.5 mM. Triacetin significantly re-
duced cell viability although this was only at dosages> 290mM. When
treated with aspirin alone, aHGG cells show limited cell death. The







maximal solubility of aspirin (SIGMA Aldrich) was 3mg/mL
(16.65 mM). We were unable to dissolve aspirin at this concentration as
significant particulate was observed. The highest concentration used
was 1mg/mL (5.55mM). Reduced aHGG cell viability was only ob-
served at 500 μM aspirin. We noted a significant reduction in aHGG cell
viability following IP1867B treatment. Aspirin alone (SIGMA) and
IP1867B noticeably changed the pH of the medium, consistent with
high concentration acetylsalicylic acid. This alone did not account for
the reduced cell viability as IP1867B significantly reduced aHGG cell
viability at lower concentrations (Fig. 1).
We determined the overall EC50 for each component and for TMZ
(Fig. 1E). Following a single treatment, IP1867B was significantly more
potent compared to each agent and single dose TMZ exposure, a re-
sponse conserved in a number of aHGG cell lines. The aHGG lines de-
monstrated high tolerance to single dose treatment with TMZ, parti-
cularly SEBTA-023, SEBTA-003 and UP-029 that display unmethylated
MGMT promoters. Representative microscopy images of each aHGG cell
line 24 h post IP1867B exposure revealed widespread cell death post-
IP1867B treatment that was not observed post-treatment with any of
the excipient components with only limited cell detachment/death
post-TMZ treatment (Fig. 1F).
Adult HGG therapeutics need to be effective under both normoxic
(21% O2) and hypoxic (1% O2) conditions. Cells were incubated under
hypoxic conditions and treated with IP1867B. At 96 h MTS assays were
conducted (under either hypoxic or normoxic conditions) and EC50
concentrations determined for each (Fig. 1G). Irrespective of the en-
vironment, there was a significant reduction in cell viability post-
IP1867B treatment. However, there was no significant difference be-
tween the EC50 values for each aHGG line cell under normoxic or
hypoxic conditions post-IP1867B exposure.
3.2. IP1867B formulation demonstrates synergy compared to each
individual excipient component and increased the effectiveness of TMZ
We questioned if the IP1867B formulation had a synergistic effect
on treated aHGG cells. We determined the effective concentration for
aspirin (SIGMA) (16 μM) and triacetin (0.6 mM) alone, an effective
concentration for aspirin (SIGMA), triacetin and saccharin (the three
excipients individually combined at 11 μM, 0.5 mM and 500mM re-
spectively) and finally for TMZ alone (9.1 μM). Single/dual agents were
added simultaneously and were compared to IP1867B (Fig. 2A–D).
Treatment with aspirin (SIGMA) and TMZ was additive (where the TMZ
EC50 fell between 6.1 and 27.2 μM for each aHGG cell line). While there
was a reduction in cell viability, this reduction was not statistically
significant. When aspirin (SIGMA) and triacetin were used in combi-
nation to treat aHGG cells no significant change was noted. A potent
synergistic response was observed when IP1867B was compared to each
excipient component, or when the three individual components were
independently combined (Fig. 2E). When aspirin (SIGMA) and TMZ
were used in combination, there was no significant difference in overall
aHGG cell viability indicating that the combination of these in vitro did
not have an additive effect (TMZ EC50 remained at 12.1 μM) (Fig. 2F).
IP1867B and TMZ when used together, showed an additive effect where
the EC50 was ≈0.5 μM (Fig. 2G). We concluded that IP1867B was
highly synergistic compared to each excipient component alone and
while aspirin (SIGMA) and TMZ in combination did not significantly
affect cell viability (either synergistic or additive), IP1867B and TMZ
did have an additive response. We questioned if non-neoplastic cells
Fig. 1. IP1867B treatment of biopsy-derived aHGG cells significantly reduces cell viability. a-d). Indicated aHGG cells (10,000 per well) were treated with
varying dosages of each indicated compound and 96 h post treatment, MTS (Promega) assays were conducted. n=3, error bars indicate ± StDev. e). Average Log2
EC50 concentration for each excipient shown. 2-tailed ANOVA analysis indicated by each bracket with P value and significance shown. n = 3 ± StDev. f).
Representative microscopy images for each biopsy-derived aHGG cell line 24 h post IP1867B treatment (40× magnification). g). Average Log2 EC50 concentration
96 h post IP1867B treatment under normoxic or hypoxic conditions. 2-tailed ANOVA analysis indicated by each bracket with P value and significance shown. n =
3 ± StDev.







were sensitive to IP1867B. Non-neoplastic CC2565 astrocytes were
exposed to each individual component or to IP1867B (Fig. 2H). At 96 h
post IP1867B, CC2565 cells did not display a significant reduction in
overall viability. IP1867B showed cancer-selectivity (EC50 concentra-
tion(s) for aHGG was between 0.39 and 0.6458 μM and the CC2565
EC50 was 10.16 μM) (P=0.0038).
3.3. IP1867B treatment induces the potent suppression of NF-κB and IGF1R
We examined how IP1867B could mediate this response. We tested
if there was significant caspase 3 cleavage following treatment with the
IP1867B (Fig. 3A). There was the significant detection of cleaved cas-
pase 3 at 96 h post-treatment. We questioned if there was p53 accu-
mulation and activation. We did not see discernible p53 accumulation
although noted p53 phosphorylation (Ser15 and Ser46) (Fig. 3B). In
SEBTA-023 aHGG cells we were unable to detect any p53. To comple-
ment this study, each aHGG cell line was exposed to IP1867B or TMZ
(100 μM) and at 24 and 96 h post treatment FACS analysis was con-
ducted (Fig. 3C). We detected significant accumulation of asub-G1 cell
population consistent with cell death post IP1867B treatment. At 96 h
post-treatment, TMZ exposure also increased the sub-G1 cell popula-
tion, however this was significantly lower compared to IP1867B treated
aHGG cells.
We evaluated the aHGG transcription response post IP1867B ex-
posure and examined a diverse range of cell death networks, the NF-κB
pathway, and the inflammation response (Fig. 3D, E and F). Three
housekeeping genes Beta-2-microglobulin (B2M), hypoxanthine phos-
phoribosyltransferase 1 (HRPT1) and Glyceraldehyde 3-phosphate dehy-
drogenase (GAPDH) were used for data normalization, and the fold
change for each gene of interest was calculated. 12 h post IP1867B
treatment, we noted a significant down regulation of various pro-in-
flammatory genes including interlukin (IL)12A, IL18, IL4, IL5, IL6, IL6-
receptor, tumour necrosis factor (TNF), TNF-receptor 1A and TNF-receptor
11B (Fig. 3G). When treated with IP1867B, aHGG cells directed a sig-
nificant transcription increase in IL11. IL6 drives many of cancer
hallmarks via the downstream activation of STAT3. IL11 has been
shown to direct a more prominent role compared to IL6 in inflamma-
tion associated cancers, suggesting a potential compensatory me-
chanism directed by aHGG following IP1867B exposure [25]. These
data raise the hypothesis that IP1867B could significantly complement
a number of IL11 inhibitors (such as Bazedoxifene and mIL-11 Mutein)
currently being tested in various gastrointestinal and breast cancers
[25–27].
The related genes Insulin-like growth factor 1 (IGF1) and Insulin-like
growth factor 1 receptor (IGF1R) were identified by our analysis post-
IP1867B treatment (Fig. 3G). IGF1 and IGF1R both showed a highly
significant expression decrease of 9.42 and 7.39 fold versus untreated
aHGG cells respectively. IGF1 and IGF1R can confer chemo-resistance
and have been considered important for EGFR inhibitor resistance [28].
These data suggested that IP1867B could significantly inhibit IGF1 and
IGF1R by potently reducing their expression and may, sensitise aHGGs
to these therapeutics. Following IP1867B treatment, we noted subtle,
although statistically significant, increases in caspase 3, caspase 6 and
caspase 9 expression supporting the induction of apoptosis (Fig. 3G). We
observed the direct repression of EGFR (2.73 fold reduction) post-
IP1867B treatment of UP-029 aHGG cells. These aHGG lines showed
significant EGFR over expression and suggested a second mechanism
where IP1867B could significantly enhance the effectiveness of aHGG
therapeutics, in particular EGFR inhibitors supported by IL4 and IL6
repression.
We broadened our findings and included additional, recent biopsy-
derived aHGG cell lines (Fig. 4A, B and C). IP1867B directed an anti-
inflammatory transcription response, characterized by the repression of
IL6, IL6-receptor, TNF, TNF-receptor 1A and the significant induction of
IL11. There was a significant reduction of EGFR, IGF1 and IGF1R
transcription. We questioned if these transcriptional data were con-
served at the protein level and noted that there was a considerable
reduction of IGF1R, IL6R and EGFR protein expression post-IP1867B
treatment in our aHGG cells (Fig. 4D). These data raised the interesting
hypothesis that IP1867B treatment could complement EGFR inhibitors.
Fig. 2. IP1867B demonstrates synergy compared to each excipient component when patient-derived aHGG cells are treated. a-d). Representative iso-
bolograms from combination or single treatment of aspirin (SIGMA), triacetin, IP1867B or temozolomide in aHGG cell lines. a). UP-029, b). SEBTA-025, c). SEBTA-
003, d). SEBTA-023 cells were treated with each effective 50% concentration. IP1867B (or temozolomide) was added to each cell line. EC50 values were determined
from dose-response curves. The straight line connects the EC50 values for each agent alone and illustrates the theoretical values resulting in additive effects. Data
points below the line represent synergistic (CI≤ 0.8) and above the line antagonistic (CI≥ 1.2) interactions. n=3. e-f). Representative isobolograms from com-
bination or single treatment of aHGG cells with IP167B and TMZ or aspirin and TMZ. n=3 g). Representative isbologram dose curves for UP-029 aHGG cells treated
with each indicated agent. h). CC2565 cells (10,000 per well) were treated with varying dosages of each indicated compound and 96 h post treatment, MTS
(Promega) assays were conducted. n=3, error bars indicate ± StDev.






Fig. 3. IP1867B directs significant cell death and suppression of key inflammatory networks in aHGGs. a). Representative immunoblots for caspase 3 cleavage
following IP1867B or TMZ exposure. b). Total p53 accumulation and activation in aHGG cells post-IP1867B treatment. c). FACS analysis 96 h post-drug treatment. d-
f). Volcano plots for cell death pathway, IL6/STAT3 and NF-κB signalling networks following IP1867B treatment of UP-029 aHGG cells. g). Key up and down-
regulated gene expression changes identified in d-f 24 h post-IP1867B treatment of UP-029 aHGG cells. n=3, error bars indicate ± StDev with P values shown.







We treated our aHGG cell lines with Gefitinib (EC50 5 μM/L), AZD3759
(EC50 50 nM) alone or in combination with IP1867B (Fig. 4E and F).
Adult HGG cells showed limited sensitivity to Gefitinib and AZD3759
however, when used in combination with IP1867B, there was a sig-
nificant increase in sensitivity to each agent. Each inhibitor was effec-
tive as a significant loss of detectable pY1068-EGFR was noted fol-
lowing exposure with Gefitnib and AZD3759 (Fig. 4G). EGFRvIII has
been shown to be a direct regulator of STAT3. It was compelling that
IP1867B treatment supressed this response [29]. IP1867B treatment in
UP-029 and SEBTA-023 aHGG cells triggered a reduction in this net-
work although we still detected, albeit reduced, EGFR and pY1068-
EGFR. In untreated, Gefitinib, or AZD3759, treated aHGG cells, there
was robust detection of IGF1R. Post-IP1867B treatment there was a
significant reduction of IGF1R protein expression. The IGF1R pathway
is an important receptor tyrosine kinase (RTK) in aHGG tumours [23].
In aHGG cells with high IGF1R expression, we detected high levels of
Fig. 4. IP1867B treatment significantly suppresses EGFR, IGF1 and IGF1R expression and enhances anti-EGFR therapeutics. a-c) Gene expression analysis in
each indicated aHGG cell line 24 h post IP1867B treatment n=3, error bars indicate ± StDev. d). Representative immunoblots for each indicated protein 24 h post
IP1867B treatment. e-f). UP-029 aHGG cells (10,000 per well) were treated with varying dosages of each indicated compound and EGFR-inhibitor and 96 h post
treatment, MTS (Promega) assays were conducted. n=3, error bars indicate ± StDev. g). Representative immunoblot for pSer473-AKT following treatment with
each single or combination therapeutic. h). Expression of key FOXO3a-dependent genes 24 h post-treatment with each indicated therapeutic. n = 3, error bars
indicate ± StDev. Two-tailed ANOVA analysis conducted for each bracket. * indicates P value≤ 0.05.
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pSer473 AKT (Fig. 4G). Neither Gefitinib nor AZD3759 had a significant
impact on pSer473 AKT level, although IP1867B treatment noticeably
reduced the level of pSer473 AKT. Concomitantly, we noted elevated
FOXO3a-dependent gene expression post-IP1867B treatment (Fig. 4H).
These data indicated that there was significant suppression of the in-
flammation response and the IGF1R network, including AKT, which
together increased the effectiveness of EGFR inhibitors.
3.4. IP1867B effectively repressed aHGG growth in intracranial implanted
tumours
The in vivo effectiveness of IP1867B was addressed using a U87-
luciferase model. U87-MG-luciferase aHGG cells were intracranially
implanted into NOD/SCID mice (six mice per group) and 7 days post-
inoculation, luciferase activity was measured. Tumour-bearing mice
were treated on day 1, 3, 5, 8, 10 and 12 by intraperitoneal (IP) in-
jection of vehicle, IP1867B (30mg/kg) or TMZ (50mg/kg) (Fig. 5A).
There was a significant reduction in luciferase expression in IP1867B
treated mice and a significant increase in survival (Fig. 5B). We col-
lected the brain and liver of each animal. We noted significant in-
tracranial tumour in vehicle treated mice, in particular, gross disruption
of brain architecture and disruption of the midline. TMZ and IP1867B
treated brains showed “normal” brain structure (Fig. 5C). We carefully
monitored animal weight and behaviour and noted there was no sig-
nificant weight loss in IP1867B treatment group (Fig. 5D). A concern
regarding high dose aspirin treatment was potential damage and lesion
development within the gastrointestinal tract. In an independent (non-
tumour bearing mouse study) we examined if IP1867B oral adminis-
tration induced any gastric mucosal lesions (Fig. 5E). There were sig-
nificantly less total mucosal membrane lesions in addition to sig-
nificantly reduced lesion frequency (per mm) in IP1867B treated mice
versus aspirin treated mice (Fig. 5F).
IP1867B treatment of tumour bearing mice significantly reduced
IGF1 and IGF1R in vivo expression and, in agreement with our in vitro
data, there was a significant down regulation of multiple inflammatory
genes in the treated tumours (Fig. 5G and H). There was an upregula-
tion of caspase 3 and caspase 9 transcription in the IP1867B treated mice
brains although this induction was not seen in the matched livers (data
not shown). A number of apoptotic markers were upregulated in the
brains and livers of TMZ treated mice. This was both tumour specific (as
measured using human-specific primers) and systemic (determined
using mouse specific primers). Following IP1867B exposure, there was
a significant downregulation of EGFR protein expression in the tumours
of treated mice (Fig. 5I). This downregulation was not observed fol-
lowing mock or TMZ treatment regimens.
4. Discussion
The gold standard treatment for aHGG patients is the “Stupp pro-
tocol” with temozolomide. Despite this aggressive multi-modal re-
gimen, patient prognosis remains poor with median survival of ap-
proximately 15 months.
The nonsteroidal anti-inflammatory agent aspirin is widely used for
preventing and treating cardiovascular and cerebrovascular diseases
while recent cohort analysis has suggested that aspirin may prevent a
range of cancers (including colon, gastric and pancreatic cancer)
[30–33]. There is accumulating evidence that aspirin may act in dif-
ferent cell types, including epithelial cells, tumour cells, endothelial
cells, platelet, and immune cells. Consequently, aspirin could act on
multiple cancer hallmarks including cell growth, metastasis, angio-
genesis and inflammation. There are noted side effects during long-term
low dose aspirin treatment regimens that include nausea, vomiting, and
abdominal pain. An important clinical complication following long-
term aspirin administration is gastrointestinal injury, in particular
gastroduodenal destruction, ulceration, and haemorrhage(s) [34]. The
risk of major bleeding following aspirin treatment is higher in patients
aged 75 years or older [34]. The median age at diagnosis of aHGG is 64
[35,36] where the incidence increases with age peaking between 75
and 84 years and this could present a major clinical obstacle for stan-
dard aspirin to be considered as a preventative or combinational
therapy for aHGG patients.
Here we evaluated, IP1867B, a “true liquid” aspirin formulation.
IP1867B allowed a higher concentration of ASA to be delivered in vitro,
directed a potent anti-aHGG response and was well tolerated by non-
neoplastic astrocytes. Compared to each excipient component, IP1867B
was synergistic and directed a potent anti-aHGG response independent
of MGMT promoter methylation. There was induction of apoptosis
following IP1867B treatment, consistent with caspase 3 cleavage. One
of our biopsy-derived aHGG cells had no detectable p53 protein al-
though was sensitive to IP1867B, suggesting that the mechanism of
action was likely p53-independent. There was significant suppression of
the NF-κB and IL6/STAT3 pathways and in particular suppression of
EGFR transcription post-IP1867B exposure. We validated the suppres-
sion of EGFR transcription and noted the concomitant reduction of
EGFR protein expression. A number of anti-EGFR clinical trials have
been instigated and for aHGG [37,38]. Our data suggested that IP1867B
could complement EGFR inhibitors. We evaluated Getfinib and
AZD3759 alone and in combination with IP1867B. Dual treatment with
IP1867B significantly increased the potency of two EGFR inhibitors and
significantly reduced ser473-AKT phosphorylation in two in vitro aHGG
models. We examined the transcription of IGF1 and IGF1R as these have
been implicated in EGFR signalling and could inhibit AKT activation.
IP1867B treatment significantly reduced IGF1 and IGF1R transcription.
These data were highly unexpected and compelling as to date there are
no blood-brain barrier permissive anti-IGF1 and IGF1R treatments.
Metabolic complications such as obesity, hyperglycemia, and type 2
diabetes are associated with poor outcomes in aHGG patients. To con-
trol peritumoral edema, high-dose steroids usage is common which can
result in de novo diabetic symptoms. These could activate IGF1 and
IGF1R in aHGG cells. The administration of IP1867B could significantly
attenuate these treatment complications noted in aHGG patients.
IP1867B showed discernibly less propensity in producing gastric
injury and induced significantly less gastric mucosal lesions compared
to conventional aspirin. There was no significant difference between
vehicle and IP1867B treated mice. The IP administration of IP1867B
caused a significant reduction in overall intracranial tumour mass and
was well tolerated. Tumour-bearing mice showed no significant weight
loss or behavioural changes indicative of tumour burden. Both in vitro
and in vivo IP1867B treatment revealed a reduction of EGFR in addition
to reduced IGF1 and IGF1R expression.
These data warrant follow-up in combination with EGFR inhibitors
and validation of 1P1867B as a putative IGF1 and IGF1R inhibitor. Care
Fig. 5. IP1867B IP treatment induces significant reduction of intracranial tumours. a) Overall luciferase signal at day 19 following IP treatment of U87-MG
tumour bearing mice. Brackets indicate two-tailed ANOVA with P values shown for each. Significant reduction of U87-luciferase tumours 19 days post IP1867B
treatment. Representative tumour bearing mouse bioilluminescence images post treatment with vehicle only (NT), TMZ or IP1867B. b). Overall survival for each
group following mock, TMZ or IP1867B IP administration. C). Representative whole brain images following PBS, IP1867B or TMZ treatment. White arrows highlight
tumour/distortion following tumour growth d). Average mice weight following vehicle only, TMZ or IP1867B treatment on day 7 or day 19 post tumour estab-
lishment. Brackets indicate two-tailed ANOVA analysis with P values shown for each comparison. e). Representative microscopic images of the gastric mucosa tract
following control, aspirin or IP1867B oral delivery. f). (left) Quantitative analysis of gastrointestinal mucosal lesion formation following control, aspirin or IP1867B
oral delivery. (right) lesion number/mm following the same treatment regimen shown in e-f. g-h). Gene expression analysis in U87-MG tumours treated with either
IP1867B or TMZ at day 19 n=3, error bars indicate ± StDev. i). Representative immunoblot for EGFR following in vivo treatment with each therapeutic at day 19.







is required as IGF1 and IGF1R have important functions in metabolism
thus the prolonged blockade of this pathway may be associated with
adverse effects. Agents that can penetrate the blood-brain barrier and
complement conventional and novel therapeutics are of significant in-
terest and warrant follow-up investigation.
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